PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 400 shares, a growth of 100.0% from the December 31st total of 200 shares. Based on an average daily trading volume, of 1,700 shares, the days-to-cover ratio is currently 0.2 days.
PureTech Health Price Performance
Shares of NASDAQ PRTC traded down $0.96 during midday trading on Friday, hitting $32.51. 2,443 shares of the company traded hands, compared to its average volume of 518. PureTech Health has a 12-month low of $18.15 and a 12-month high of $43.57. The stock has a 50-day moving average price of $32.79 and a 200 day moving average price of $29.14.
Get PureTech Health alerts:Hedge Funds Weigh In On PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. increased its holdings in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 660,000 shares of the company's stock after acquiring an additional 630,000 shares during the period. AWM Investment Company Inc. owned approximately 2.32% of PureTech Health worth $2,513,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.25% of the company's stock.
About PureTech Health
(Get Rating)PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
See Also
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.